Anecortave Acetate for the Treatment of Exudative Age-Related Macular Degeneration—A Review of Clinical Outcomes
Authors:
- Stephen R. RussellSRStephen R. Russell
- Henry L. HudsonHHHenry L. Hudson
- Janice A. JerdanJJJanice A. Jerdan
- 1 January 2007
- journal article
- review article
- Published by Elsevier in Survey of Ophthalmology
- Vol. 52 (1) , S79-S90
Abstract
No abstract availableKeywords
This publication has 22 references indexed in Scilit:
- Posterior Juxtascleral Depot Administration of Anecortave AcetateSurvey of Ophthalmology, 2007
- Anecortave Acetate (15 Milligrams) versus Photodynamic Therapy for Treatment of Subfoveal Neovascularization in Age-Related Macular DegenerationOphthalmology, 2006
- Immunohistopathologic evaluation of choroidal neovascular membranes following Verteporfin-photodynamic therapyAmerican Journal of Ophthalmology, 2004
- Anecortave acetate as monotherapy for treatment of subfoveal neovascularization in age-related macular degenerationOphthalmology, 2003
- Effect of lesion size, visual acuity, and lesion composition on visual acuity change with and without verteporfin therapy for choroidal neovascularization secondary to age-related macular degeneration: TAP and VIP report no. 1American Journal of Ophthalmology, 2003
- Changes in confocal indocyanine green angiography through two years after photodynamic therapy with verteporfinOphthalmology, 2003
- ANECORTAVE ACETATE AS MONOTHERAPY FOR THE TREATMENT OF SUBFOVEAL LESIONS IN PATIENTS WITH EXUDATIVE AGE-RELATED MACULAR DEGENERATION (AMD)Retina, 2003
- Statins Have Biphasic Effects on AngiogenesisCirculation, 2002
- Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization—verteporfin in photodynamic therapy report 2American Journal of Ophthalmology, 2001
- AL-3789: a novel ophthalmic angiostatic steroidExpert Opinion on Investigational Drugs, 1997